

# The cancer microbiome

Nature Reviews Cancer

19, 371-376

DOI: [10.1038/s41568-019-0155-3](https://doi.org/10.1038/s41568-019-0155-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Gut microbes as a therapeutic armory. <i>Drug Discovery Today: Disease Models</i> , 2018, 28, 51-59.	1.2	3
2	Model systems for the study of how symbiotic associations between animals and extracellular bacterial partners are established and maintained. <i>Drug Discovery Today: Disease Models</i> , 2018, 28, 3-12.	1.2	5
3	Role of microbes, metabolites and effector compounds in host-microbiota interaction: a pharmacological outlook. <i>Environmental Chemistry Letters</i> , 2019, 17, 1801-1820.	8.3	14
4	Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 41.	7.1	150
5	Phage warriors. <i>Nature Reviews Cancer</i> , 2019, 19, 544-545.	12.8	2
6	Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4584.	1.8	72
7	Fungi accelerate pancreatic cancer. <i>Nature</i> , 2019, 574, 184-185.	13.7	12
8	MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2019, 9, 1404.	1.3	53
9	Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 1001-1003.	1.1	2
10	Frontiers in Cancer Immunotherapy: Understanding the Role of Gut Microbiota. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 2-2.	0.9	3
11	Tumor Microenvironment. <i>Medicina (Lithuania)</i> , 2020, 56, 15.	0.8	677
12	Benevolent viruses in skin cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 2-2.	12.8	1
13	Mã©nage Å trois: regulation of host immunity by enteric neuro-immune-microbiota cross talks. <i>Current Opinion in Neurobiology</i> , 2020, 62, 26-33.	2.0	5
14	Early life antibiotic exposure and host health: Role of the microbiota-immune interaction. <i>Seminars in Perinatology</i> , 2020, 44, 151323.	1.1	4
15	The microbiome: An emerging key player in aging and longevity. <i>Translational Medicine of Aging</i> , 2020, 4, 103-116.	0.6	76
16	Unique and common traits in mycorrhizal symbioses. <i>Nature Reviews Microbiology</i> , 2020, 18, 649-660.	13.6	277
17	Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 565470.	2.2	63
18	MR1-Restricted T Cells in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 2145.	1.7	13

#	ARTICLE	IF	CITATIONS
19	Editorial: The Human Microbiome and Cancer. <i>Frontiers in Microbiology</i> , 2020, 11, 1514.	1.5	1
20	Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy. <i>Frontiers in Oncology</i> , 2020, 10, 568939.	1.3	15
21	Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9. <i>British Journal of Cancer</i> , 2020, 123, 1469-1470.	2.9	1
22	Microbiome Patterns in Matched Bile, Duodenal, Pancreatic Tumor Tissue, Drainage, and Stool Samples: Association with Preoperative Stenting and Postoperative Pancreatic Fistula Development. <i>Journal of Clinical Medicine</i> , 2020, 9, 2785.	1.0	16
23	<p>Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 271-288.	1.8	16
24	Microbiome in cancer progression and therapy. <i>Current Opinion in Microbiology</i> , 2020, 56, 118-126.	2.3	11
25	Intervention strategies for microbial therapeutics in cancer immunotherapy. <i>Immuno-Oncology Technology</i> , 2020, 6, 9-17.	0.2	8
26	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 784.	2.2	339
27	Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy. <i>Current Opinion in Pharmacology</i> , 2020, 54, 1-10.	1.7	35
28	Gut microbiome, big data and machine learning to promote precision medicine for cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 635-648.	8.2	172
29	Microbial defence against cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 200-200.	12.8	6
30	Gut microbiome in HCC – Mechanisms, diagnosis and therapy. <i>Journal of Hepatology</i> , 2020, 72, 230-238.	1.8	206
31	Cervicovaginal Microbiome and Urine Metabolome Paired Analysis Reveals Niche Partitioning of the Microbiota in Patients with Human Papilloma Virus Infections. <i>Metabolites</i> , 2020, 10, 36.	1.3	24
32	Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis. <i>Cancer Letters</i> , 2020, 481, 32-44.	3.2	15
33	Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 318, H1474-H1486.	1.5	48
34	Hierarchically Labeled Database Indexing Allows Scalable Characterization of Microbiomes. <i>IScience</i> , 2020, 23, 100988.	1.9	7
35	Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics. <i>Frontiers in Pharmacology</i> , 2020, 11, 390.	1.6	56
36	Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 403-421.	1.3	7

#	ARTICLE	IF	CITATIONS
37	Microbiome and host crosstalk: A new paradigm to cancer therapy. <i>Seminars in Cancer Biology</i> , 2021, 70, 71-84.	4.3	18
38	Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. <i>Seminars in Cancer Biology</i> , 2021, 70, 11-23.	4.3	26
39	Targeting cancer-promoting inflammation "have anti-inflammatory therapies come of age?". <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 261-279.	12.5	171
40	Deep Tumor Profiling for Molecular Tumor Boards. , 2021, , 352-360.		0
41	Gut Microbiome and Cancer. <i>The Microbiomes of Humans, Animals, Plants, and the Environment</i> , 2021, , 93-168.	0.2	0
42	Mycobiota dysbiosis and gastric tumorigenesis. <i>Theranostics</i> , 2021, 11, 7488-7490.	4.6	10
43	<i>P. aeruginosa</i> Mediated Necroptosis in Mouse Tumor Cells Induces Long-Lasting Systemic Antitumor Immunity. <i>Frontiers in Oncology</i> , 2020, 10, 610651.	1.3	4
44	Dysbiosis of Oral Microbiota During Oral Squamous Cell Carcinoma Development. <i>Frontiers in Oncology</i> , 2021, 11, 614448.	1.3	47
45	Systemic Immunoregulatory Consequences of Gut Commensal Translocation. <i>Trends in Immunology</i> , 2021, 42, 137-150.	2.9	26
46	The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants. <i>Cell Host and Microbe</i> , 2021, 29, 281-298.e5.	5.1	109
47	Cancer Microbiome; Opportunities and Challenges. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 215-229.	0.6	4
48	Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution. <i>Cancers</i> , 2021, 13, 1380.	1.7	38
49	Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go. <i>Journal of Personalized Medicine</i> , 2021, 11, 216.	1.1	44
50	Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot Study. <i>Frontiers in Oncology</i> , 2021, 11, 604584.	1.3	16
51	Linking pollution and cancer in aquatic environments: A review. <i>Environment International</i> , 2021, 149, 106391.	4.8	42
52	Detection of cell-free microbial DNA using a contaminant-controlled analysis framework. <i>Genome Biology</i> , 2021, 22, 187.	3.8	22
53	Exploring the Potential of Breast Microbiota as Biomarker for Breast Cancer and Therapeutic Response. <i>American Journal of Pathology</i> , 2021, 191, 968-982.	1.9	21
54	<i>Pseudocapillaria tomentosa</i> , <i>Mycoplasma</i> spp., and Intestinal Lesions in Experimentally Infected Zebrafish <i>Danio rerio</i> . <i>Zebrafish</i> , 2021, 18, 207-220.	0.5	12

#	ARTICLE	IF	CITATIONS
55	Gut Microbiota in Cancer Immune Response and Immunotherapy. Trends in Cancer, 2021, 7, 647-660.	3.8	136
56	A Crosstalk between Diet, Microbiome and microRNA in Epigenetic Regulation of Colorectal Cancer. Nutrients, 2021, 13, 2428.	1.7	18
57	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822.	1.8	17
58	Metabolic programming in dendritic cells tailors immune responses and homeostasis. Cellular and Molecular Immunology, 2022, 19, 370-383.	4.8	38
59	Harness the functions of gut microbiome in tumorigenesis for cancer treatment. Cancer Communications, 2021, 41, 937-967.	3.7	18
60	Fungi, host immune response, and tumorigenesis. American Journal of Physiology - Renal Physiology, 2021, 321, G213-G222.	1.6	13
61	Microbiota and prostate cancer. Seminars in Cancer Biology, 2022, 86, 1058-1065.	4.3	23
63	Nutrition and Cancer Risk from the Viewpoint of the Intestinal Microbiome. Nutrients, 2021, 13, 3326.	1.7	7
64	The intratumoural microbiota in cancer: new insights from inside. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188626.	3.3	13
65	Commensal microbiota in the digestive tract: a review of its roles in carcinogenesis and radiotherapy. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	2
67	Microbial-based cancer therapyâ€”bugs as drugs: History & the essential role of medical imaging. Cancer Treatment and Research Communications, 2021, 28, 100436.	0.7	2
68	Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop. Pathogens and Immunity, 2020, 5, 143.	1.4	42
69	Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies. Frontiers in Immunology, 2019, 10, 2954.	2.2	40
70	Recent Advancements in Microbiomeâ€”Immune Homeostasis and their Involvement in Cancer Immunotherapy. , 2021, , 239-258.		1
71	Patients with Parkinsonâ€™s disease predict a lower incidence of colorectal cancer. BMC Geriatrics, 2021, 21, 564.	1.1	5
72	Combinatorial Click Chemistry Labeling to Study Live Human Gut-Derived Microbiota Communities. Frontiers in Microbiology, 2021, 12, 750624.	1.5	2
73	Microbiota, mucosal immunity, and Colon cancer. , 2020, , 157-209.		1
74	Influence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy. Pharmacological Research, 2021, 174, 105966.	3.1	22

#	ARTICLE	IF	CITATIONS
77	The microbiome: an emerging key player in aging and longevity. <i>Translational Medicine of Aging</i> , 2020, 4, 103-116.	0.6	23
78	Redrawing therapeutic boundaries: microbiota and cancer. <i>Trends in Cancer</i> , 2022, 8, 87-97.	3.8	11
79	Treatment landscape of triple-negative breast cancer “ expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 91-113.	12.5	414
80	Is There an Interplay between Oral Microbiome, Head and Neck Carcinoma and Radiation-Induced Oral Mucositis?. <i>Cancers</i> , 2021, 13, 5902.	1.7	14
81	Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma. , 2022, 10, e003069.		32
82	Artificial Intelligence and Precision Medicine: A Perspective. <i>Advances in Experimental Medicine and Biology</i> , 2021, , 1-11.	0.8	6
83	AI-aided Data Mining in Gut Microbiome: The Road to Precision Medicine. , 2021, , .		1
84	Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers. <i>Frontiers in Pharmacology</i> , 2021, 12, 775084.	1.6	12
85	A dysbiotic microbiome promotes head and neck squamous cell carcinoma. <i>Oncogene</i> , 2022, 41, 1269-1280.	2.6	32
86	Synthesis of Hemiprotonic Phenanthroline“Phenanthroline <sup>+</sup> Compounds with both Antitumor and Antimicrobial Activity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2532-2547.	2.9	6
87	Viral tag and grow: a scalable approach to capture and characterize infectious virus“host pairs. <i>ISME Communications</i> , 2022, 2, .	1.7	4
88	Strain-level fitness in the gut microbiome is an emergent property of glycans and a single metabolite. <i>Cell</i> , 2022, 185, 513-529.e21.	13.5	36
89	Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 422.	7.1	57
90	Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210779.	1.4	21
91	Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. <i>Immunity</i> , 2022, 55, 701-717.e7.	6.6	16
92	Nanotechnological interventions of the microbiome as a next-generation antimicrobial therapy. <i>Science of the Total Environment</i> , 2022, 833, 155085.	3.9	6
93	The salivary metatranscriptome as an accurate diagnostic indicator of oral cancer. <i>Npj Genomic Medicine</i> , 2021, 6, 105.	1.7	20
94	Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 367-382.	2.7	6

#	ARTICLE	IF	CITATIONS
95	Probiotic Engineering and Targeted Sonoimmunotherapy Augmented by STING Agonist. <i>Advanced Science</i> , 2022, 9, .	5.6	16
96	Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches. <i>Journal of Personalized Medicine</i> , 2022, 12, 854.	1.1	12
97	Metaomics in Clinical Laboratory: Potential Driving Force for Innovative Disease Diagnosis. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
98	It Takes Two to Tango: A Review of Oncogenic Virus and Host Microbiome Associated Inflammation in Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 3120.	1.7	7
99	Coral growth anomalies, neoplasms, and tumors in the Anthropocene. <i>Trends in Microbiology</i> , 2022, 30, 1160-1173.	3.5	4
100	Bee pollen in zebrafish diet affects intestinal microbiota composition and skin cutaneous melanoma development. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
101	Gut microbiome in gastrointestinal cancer: a friend or foe?. <i>International Journal of Biological Sciences</i> , 2022, 18, 4101-4117.	2.6	21
102	A Novel Microbiome Signature in Gastric Cancer. <i>Annals of Surgery</i> , 2022, 276, 605-615.	2.1	11
103	Obesity enriches for tumor protective microbial metabolites and treatment refractory cells to confer therapy resistance in PDAC. <i>Gut Microbes</i> , 2022, 14, .	4.3	10
105	Patient-derived cancer models: Valuable platforms for anticancer drug testing. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
106	Fasting and cancer responses to therapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 107-123.	1.6	2
108	Archaea Microbiome Dysregulated Genes and Pathways as Molecular Targets for Lung Adenocarcinoma and Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11566.	1.8	3
109	Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. <i>Communications Biology</i> , 2022, 5, .	2.0	7
110	The impact of the microbiome in cancer: Targeting metabolism of cancer cells and host. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
111	Intestine-on-a-chip for intestinal disease study and pharmacological research. <i>View</i> , 2023, 4, .	2.7	4
112	Oral Bacteriome and Mycobiome across Stages of Oral Carcinogenesis. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	10
113	The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited. <i>Cancers</i> , 2023, 15, 376.	1.7	46
114	Microbiome in Gastric Cancer. , 2023, , 41-66.		1

#	ARTICLE	IF	CITATIONS
115	Going big by going small: Trade-offs in microbiome explanations of cancer. <i>Studies in History and Philosophy of Science Part A</i> , 2023, 97, 101-110.	0.6	0
116	Big Data in Gastroenterology Research. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2458.	1.8	6
117	Influence of neo-adjuvant radiotherapy on the intestinal microbiota of rectal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6085-6096.	1.2	0
118	Colon Cancer Microbiome Landscaping: Differences in Right- and Left-Sided Colon Cancer and a Tumor Microbiome-Ileal Microbiome Association. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3265.	1.8	7
119	Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?. <i>Cancers</i> , 2023, 15, 1348.	1.7	1
120	A Review of Gut Microbiota-Derived Metabolites in Tumor Progression and Cancer Therapy. <i>Advanced Science</i> , 2023, 10, .	5.6	12
121	Forging the microbiome to help us live long and prosper. <i>PLoS Biology</i> , 2023, 21, e3002087.	2.6	1
122	Exploring the microbiome of oral epithelial dysplasia as a predictor of malignant progression. <i>BMC Oral Health</i> , 2023, 23, .	0.8	2
123	Innate lymphoid cells and innate-like T cells in cancer at the crossroads of innate and adaptive immunity. <i>Nature Reviews Cancer</i> , 2023, 23, 351-371.	12.8	15
124	Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	27
131	Gut Microbiota and Host Immune System in Cancer. , 2023, , 1-40.		0
134	Cancers make their own luck: theories of cancer origins. <i>Nature Reviews Cancer</i> , 2023, 23, 710-724.	12.8	14
137	Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling. <i>Biochip Journal</i> , 2023, 17, 403-430.	2.5	1
146	Microbiome subsets determine tumor prognosis and molecular characteristics of clear-cell renal cell carcinoma: a multi-center integrated analysis of microbiome, metabolome, and transcriptome data. <i>Frontiers of Medicine</i> , 0, , .	1.5	0